For the quarter ending 2026-03-31, IKT had -$89,646,698 decrease in cash & cash equivalents over the period. -$12,059,722 in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -16,380,840 | -12,734,651 | -11,930,280 | -23,594,258 |
| Depreciation | 0 | 0 | 23,687 | 36,812 |
| Stock-based compensation expense | 5,559,766 | 4,533,780 | 4,525,206 | 6,250,938 |
| Write-off of in-process research and development | 0 | 0 | 0 | 7,357,294 |
| Change in fair value contingent consideration | 373,354 | -642,169 | 492,827 | 1,523,284 |
| Non-cash accretion on marketable securities | 814,923 | 366,472 | 570,503 | - |
| Operating lease right-of-use assets | 0 | 0 | 34,918 | 66,519 |
| Prepaid expenses and other current assets | 949,439 | -275,411 | -249,795 | -7,526 |
| Prepaid research and development | -487,083 | 791,427 | 1,071,711 | 57,547 |
| Other assets | 60,638 | 37,208 | 57,913 | - |
| Accounts payable | 429,251 | 537,526 | -1,983,355 | 1,592,656 |
| Operating lease liabilities | 0 | 0 | 37,944 | 72,573 |
| Accrued expenses and other current liabilities | 43,372 | 424,899 | 718,197 | 258,156 |
| Net cash used in operating activities | -12,059,722 | -7,515,973 | -10,592,730 | -9,677,761 |
| Purchases of equipment and improvements | 0 | 0 | 0 | 13,399 |
| Purchases of investments - marketable securities | 90,584,587 | 98,847 | 38,996,000 | 0 |
| Maturities of investments - marketable securities | 10,100,000 | 0 | 10,249,897 | 31,350,103 |
| Acquired in-process research and development | 0 | 0 | 0 | 438,624 |
| Net cash provided by (used in) investing activities | -80,484,587 | -98,847 | -28,746,103 | 30,898,080 |
| Issuance of common stock from exercise of stock options | - | 562,915 | 250,932 | 31,621 |
| Deferred offering costs | - | - | -385,062 | - |
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs | 2,897,611 | 107,617,345 | 0 | 150 |
| Net cash provided by financing activities | 2,897,611 | 108,565,322 | -134,130 | 31,771 |
| Net increase (decrease) in cash and cash equivalents | -89,646,698 | 100,950,502 | -39,472,963 | 21,252,090 |
| Cash and cash equivalents at beginning of period | 139,220,208 | 38,269,706 | 56,490,579 | - |
| Cash and cash equivalents at end of period | 49,573,510 | 139,220,208 | 38,269,706 | - |
Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. (IKT)